Treatment Efficacy and Compliance in Patients with Diabetic Macular Edema Treated with Ranibizumab in a Real-Life Setting
Purpose. To assess real-life efficacy of ranibizumab and treatment compliance of patients with vision loss secondary to diabetic macular edema (DME). Methods. A retrospective study was conducted in DME patients treated with ranibizumab. Patients were monitored every 4 weeks for visual acuity (VA) an...
Uložené v:
| Vydané v: | Journal of ophthalmology Ročník 2018; číslo 2018; s. 1 - 7 |
|---|---|
| Hlavní autori: | , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
Cairo, Egypt
Hindawi Publishing Corporation
01.01.2018
Hindawi John Wiley & Sons, Inc Wiley |
| Predmet: | |
| ISSN: | 2090-004X, 2090-0058 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Purpose. To assess real-life efficacy of ranibizumab and treatment compliance of patients with vision loss secondary to diabetic macular edema (DME). Methods. A retrospective study was conducted in DME patients treated with ranibizumab. Patients were monitored every 4 weeks for visual acuity (VA) and central retinal thickness (CRT) by SD-OCT. All patients received a loading dose of 3 monthly injections followed by retreatments on an as-needed basis. The primary endpoint was the change in VA at M12. Patient compliance to the follow-up and the correlation between the injection number and VA were also investigated. Compliance was compared to that of neovascular age-related macular degeneration (nAMD) patients. Results. Seventy-two eyes of 55 consecutive DME patients were included. At baseline, the mean VA was 56.5 letters and CRT was 470 μm. At M12, the mean VA was 63.4 letters (p<0.0001), 31.1% of patients had a VA > 70 letters, the mean VA change was +6.9 letters, and the mean CRT was 361.9 μm (p=0.0001) after a mean number of 5.33 intravitreal injections. In patients who received ≥7 injections, the VA gain and final VA were significantly higher than in patients who received <7 injections. At M12, 25.45% of DME patients were lost to follow-up versus 16.8% of nAMD patients (n=55). Discussion/Conclusion. Our study confirms the real-life efficacy of ranibizumab in DME at M12 and the need for a large number of injections to achieve better visual outcomes. We also showed a trend to a lower compliance in diabetic versus nAMD patients. |
|---|---|
| AbstractList | Purpose. To assess real-life efficacy of ranibizumab and treatment compliance of patients with vision loss secondary to diabetic macular edema (DME). Methods. A retrospective study was conducted in DME patients treated with ranibizumab. Patients were monitored every 4 weeks for visual acuity (VA) and central retinal thickness (CRT) by SD-OCT. All patients received a loading dose of 3 monthly injections followed by retreatments on an as-needed basis. The primary endpoint was the change in VA at M12. Patient compliance to the follow-up and the correlation between the injection number and VA were also investigated. Compliance was compared to that of neovascular age-related macular degeneration (nAMD) patients. Results. Seventy-two eyes of 55 consecutive DME patients were included. At baseline, the mean VA was 56.5 letters and CRT was 470 μm. At M12, the mean VA was 63.4 letters (p<0.0001), 31.1% of patients had a VA > 70 letters, the mean VA change was +6.9 letters, and the mean CRT was 361.9 μm (p=0.0001) after a mean number of 5.33 intravitreal injections. In patients who received ≥7 injections, the VA gain and final VA were significantly higher than in patients who received <7 injections. At M12, 25.45% of DME patients were lost to follow-up versus 16.8% of nAMD patients (n=55). Discussion/Conclusion. Our study confirms the real-life efficacy of ranibizumab in DME at M12 and the need for a large number of injections to achieve better visual outcomes. We also showed a trend to a lower compliance in diabetic versus nAMD patients. Purpose. To assess real-life efficacy of ranibizumab and treatment compliance of patients with vision loss secondary to diabetic macular edema (DME). Methods. A retrospective study was conducted in DME patients treated with ranibizumab. Patients were monitored every 4 weeks for visual acuity (VA) and central retinal thickness (CRT) by SD-OCT. All patients received a loading dose of 3 monthly injections followed by retreatments on an as-needed basis. The primary endpoint was the change in VA at M12. Patient compliance to the follow-up and the correlation between the injection number and VA were also investigated. Compliance was compared to that of neovascular age-related macular degeneration (nAMD) patients. Results. Seventy-two eyes of 55 consecutive DME patients were included. At baseline, the mean VA was 56.5 letters and CRT was 470 [micro]m. At M12, the mean VA was 63.4 letters (p < 0.0001), 31.1% of patients had a VA > 70 letters, the mean VA change was +6.9 letters, and the mean CRT was 361.9 [micro]m (p = 0.0001) after a mean number of 5.33 intravitreal injections. In patients who received [greater than or equal to] 7 injections, the VA gain and final VA were significantly higher than in patients who received <7 injections. At M12, 25.45% of DME patients were lost to follow-up versus 16.8% of nAMD patients (n = 55). Discussion/Conclusion. Our study confirms the real-life efficacy of ranibizumab in DME at M12 and the need for a large number of injections to achieve better visual outcomes. We also showed a trend to a lower compliance in diabetic versus nAMD patients. To assess real-life efficacy of ranibizumab and treatment compliance of patients with vision loss secondary to diabetic macular edema (DME).PURPOSETo assess real-life efficacy of ranibizumab and treatment compliance of patients with vision loss secondary to diabetic macular edema (DME).A retrospective study was conducted in DME patients treated with ranibizumab. Patients were monitored every 4 weeks for visual acuity (VA) and central retinal thickness (CRT) by SD-OCT. All patients received a loading dose of 3 monthly injections followed by retreatments on an as-needed basis. The primary endpoint was the change in VA at M12. Patient compliance to the follow-up and the correlation between the injection number and VA were also investigated. Compliance was compared to that of neovascular age-related macular degeneration (nAMD) patients.METHODSA retrospective study was conducted in DME patients treated with ranibizumab. Patients were monitored every 4 weeks for visual acuity (VA) and central retinal thickness (CRT) by SD-OCT. All patients received a loading dose of 3 monthly injections followed by retreatments on an as-needed basis. The primary endpoint was the change in VA at M12. Patient compliance to the follow-up and the correlation between the injection number and VA were also investigated. Compliance was compared to that of neovascular age-related macular degeneration (nAMD) patients.Seventy-two eyes of 55 consecutive DME patients were included. At baseline, the mean VA was 56.5 letters and CRT was 470 μm. At M12, the mean VA was 63.4 letters (p < 0.0001), 31.1% of patients had a VA > 70 letters, the mean VA change was +6.9 letters, and the mean CRT was 361.9 μm (p = 0.0001) after a mean number of 5.33 intravitreal injections. In patients who received ≥7 injections, the VA gain and final VA were significantly higher than in patients who received <7 injections. At M12, 25.45% of DME patients were lost to follow-up versus 16.8% of nAMD patients (n = 55).RESULTSSeventy-two eyes of 55 consecutive DME patients were included. At baseline, the mean VA was 56.5 letters and CRT was 470 μm. At M12, the mean VA was 63.4 letters (p < 0.0001), 31.1% of patients had a VA > 70 letters, the mean VA change was +6.9 letters, and the mean CRT was 361.9 μm (p = 0.0001) after a mean number of 5.33 intravitreal injections. In patients who received ≥7 injections, the VA gain and final VA were significantly higher than in patients who received <7 injections. At M12, 25.45% of DME patients were lost to follow-up versus 16.8% of nAMD patients (n = 55).Our study confirms the real-life efficacy of ranibizumab in DME at M12 and the need for a large number of injections to achieve better visual outcomes. We also showed a trend to a lower compliance in diabetic versus nAMD patients.DISCUSSION/CONCLUSIONOur study confirms the real-life efficacy of ranibizumab in DME at M12 and the need for a large number of injections to achieve better visual outcomes. We also showed a trend to a lower compliance in diabetic versus nAMD patients. To assess real-life efficacy of ranibizumab and treatment compliance of patients with vision loss secondary to diabetic macular edema (DME). A retrospective study was conducted in DME patients treated with ranibizumab. Patients were monitored every 4 weeks for visual acuity (VA) and central retinal thickness (CRT) by SD-OCT. All patients received a loading dose of 3 monthly injections followed by retreatments on an as-needed basis. The primary endpoint was the change in VA at M12. Patient compliance to the follow-up and the correlation between the injection number and VA were also investigated. Compliance was compared to that of neovascular age-related macular degeneration (nAMD) patients. Seventy-two eyes of 55 consecutive DME patients were included. At baseline, the mean VA was 56.5 letters and CRT was 470 m. At M12, the mean VA was 63.4 letters ( < 0.0001), 31.1% of patients had a VA > 70 letters, the mean VA change was +6.9 letters, and the mean CRT was 361.9 m ( = 0.0001) after a mean number of 5.33 intravitreal injections. In patients who received ≥7 injections, the VA gain and final VA were significantly higher than in patients who received <7 injections. At M12, 25.45% of DME patients were lost to follow-up versus 16.8% of nAMD patients ( = 55). Our study confirms the real-life efficacy of ranibizumab in DME at M12 and the need for a large number of injections to achieve better visual outcomes. We also showed a trend to a lower compliance in diabetic versus nAMD patients. Purpose . To assess real-life efficacy of ranibizumab and treatment compliance of patients with vision loss secondary to diabetic macular edema (DME). Methods . A retrospective study was conducted in DME patients treated with ranibizumab. Patients were monitored every 4 weeks for visual acuity (VA) and central retinal thickness (CRT) by SD-OCT. All patients received a loading dose of 3 monthly injections followed by retreatments on an as-needed basis. The primary endpoint was the change in VA at M12. Patient compliance to the follow-up and the correlation between the injection number and VA were also investigated. Compliance was compared to that of neovascular age-related macular degeneration (nAMD) patients. Results . Seventy-two eyes of 55 consecutive DME patients were included. At baseline, the mean VA was 56.5 letters and CRT was 470 μ m. At M12, the mean VA was 63.4 letters ( p < 0.0001 ), 31.1% of patients had a VA > 70 letters, the mean VA change was +6.9 letters, and the mean CRT was 361.9 μ m ( p = 0.0001 ) after a mean number of 5.33 intravitreal injections. In patients who received ≥7 injections, the VA gain and final VA were significantly higher than in patients who received <7 injections. At M12, 25.45% of DME patients were lost to follow-up versus 16.8% of nAMD patients ( n = 55 ). Discussion/Conclusion . Our study confirms the real-life efficacy of ranibizumab in DME at M12 and the need for a large number of injections to achieve better visual outcomes. We also showed a trend to a lower compliance in diabetic versus nAMD patients. |
| Audience | Academic |
| Author | Quentel, Gabriel Giocanti-Auregan, Audrey Delahaye-Mazza, Corinne Grenet, Typhaine Cohen, Salomon Yves Nghiem-Buffet, Sylvia Best, Anne-Laurence Fajnkuchen, Franck |
| AuthorAffiliation | 1 Ophthalmology Department, Avicenne Hospital, DHU Vision and Handicaps, APHP, Paris 13 University, Bobigny, France 2 Centre d'Imagerie et de Laser, Paris, France 3 Ophthalmology Department, Centre Hospitalier Intercommunal de Créteil, Paris Est University, Créteil, France |
| AuthorAffiliation_xml | – name: 1 Ophthalmology Department, Avicenne Hospital, DHU Vision and Handicaps, APHP, Paris 13 University, Bobigny, France – name: 2 Centre d'Imagerie et de Laser, Paris, France – name: 3 Ophthalmology Department, Centre Hospitalier Intercommunal de Créteil, Paris Est University, Créteil, France |
| Author_xml | – sequence: 1 fullname: Giocanti-Auregan, Audrey – sequence: 2 fullname: Delahaye-Mazza, Corinne – sequence: 3 fullname: Quentel, Gabriel – sequence: 4 fullname: Grenet, Typhaine – sequence: 5 fullname: Nghiem-Buffet, Sylvia – sequence: 6 fullname: Fajnkuchen, Franck – sequence: 7 fullname: Best, Anne-Laurence – sequence: 8 fullname: Cohen, Salomon Yves |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29850205$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFku9r1DAYx4tM3Jx752spCCLobUmapM0bYZynDk6UOcF34Wl-3GW0ydmmjvOvN92d524oNtCW5PN8nyfP832cHfjgTZY9xegUY8bOCMLVGeUYYSIeZEcECTRBiFUHu3_67TA76ftrlJ4CU8bQo-yQiIohgthRtr7qDMTW-JjPrHUK1DoHr_NpaFeNA69M7nz-GaJLSJ_fuLjM3zqoTXQq_whqaKDLZ9q0kN8qGb1hLsG72v0cWqhHAcgvDTSTubMm_2JidH7xJHtooenNyfZ7nH19N7uafpjMP72_mJ7PJ4oXLE5qTbioMVG8LGrDmK6oLZARqIRSFZpzwSsLmmrLka2pNWVlKiFoYTVXTFTFcXax0dUBruWqcy10axnAyduN0C0kdOk2jZFlxREvSlsRbSirRa3qUgngilNkERq13my0VkPdGq1STzpo9kT3T7xbykX4IZkoCK1wEni5FejC98H0UbauV6ZpwJsw9JIgWgosKKMJfX4PvQ5D51OrJKGo5EVF02tHLSBdwHkbUl41ispzJhBnGJGx7tO_UGmlwTmVLGVd2t8LeHEnYJlmF5d9aIbogu_3wWd3O7JrxW-HJeD1BlBd6PvO2B2CkRw9LEcPy62HE07u4cpFGNOmil3zr6BXm6Cl8xpu3P9SbEtOpk0J4A-NBU-DKn4Bv4YHCA |
| CitedBy_id | crossref_primary_10_1038_s41433_025_03835_w crossref_primary_10_3390_pharmaceutics15102461 crossref_primary_10_1111_aos_15799 crossref_primary_10_1155_2020_6979758 crossref_primary_10_1038_s41598_021_98568_7 crossref_primary_10_1111_ceo_13845 crossref_primary_10_1001_jamaophthalmol_2025_0001 crossref_primary_10_1159_000503036 crossref_primary_10_1177_2474126420953067 crossref_primary_10_1080_02713683_2018_1543708 crossref_primary_10_1007_s40123_023_00672_6 crossref_primary_10_3390_jcm11175200 crossref_primary_10_1177_1120672119861623 crossref_primary_10_1038_s41433_020_1048_0 crossref_primary_10_1007_s00417_020_04944_w crossref_primary_10_1159_000511591 crossref_primary_10_2147_OPTH_S313081 crossref_primary_10_1177_11206721221117695 crossref_primary_10_2147_OPTH_S248661 crossref_primary_10_1177_24741264231156096 crossref_primary_10_3389_fmed_2021_781421 crossref_primary_10_1055_a_2419_1794 crossref_primary_10_1097_IAE_0000000000002716 crossref_primary_10_2147_OPTH_S237586 crossref_primary_10_1186_s13643_020_01562_9 crossref_primary_10_1007_s00592_020_01513_9 crossref_primary_10_1177_11206721211052852 crossref_primary_10_7759_cureus_34669 |
| Cites_doi | 10.2147/OPTH.S100764 10.1001/archopht.1985.01050120030015 10.1016/j.ophtha.2011.12.039 10.1016/j.ophtha.2014.08.047 10.1016/j.diabres.2016.09.015 10.2337/dc10-0493 10.1136/bjophthalmol-2013-303232 10.1159/000453006 10.1016/j.diabet.2009.06.002 10.1016/j.ophtha.2009.04.049 10.1185/03007995.2015.1081880 10.1016/j.ophtha.2010.09.029 10.1038/eye.2011.337 10.1056/NEJMoa054481 10.1016/j.ajo.2009.01.024 10.1016/j.ophtha.2010.12.033 10.1016/j.ophtha.2014.07.002 10.1136/bjophthalmol-2015-307249 10.1001/archophthalmol.2010.21 10.1016/j.ophtha.2008.06.015 10.1016/j.ophtha.2008.10.018 10.1038/eye.2015.209 10.1016/j.ophtha.2006.02.065 |
| ContentType | Journal Article |
| Copyright | Copyright © 2018 Anne-Laurence Best et al. COPYRIGHT 2018 John Wiley & Sons, Inc. Copyright © 2018 Anne-Laurence Best et al. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Copyright © 2018 Anne-Laurence Best et al. 2018 |
| Copyright_xml | – notice: Copyright © 2018 Anne-Laurence Best et al. – notice: COPYRIGHT 2018 John Wiley & Sons, Inc. – notice: Copyright © 2018 Anne-Laurence Best et al. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Copyright © 2018 Anne-Laurence Best et al. 2018 |
| DBID | ADJCN AHFXO RHU RHW RHX AAYXX CITATION NPM 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 5PM DOA |
| DOI | 10.1155/2018/4610129 |
| DatabaseName | الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete Hindawi Publishing Complete Hindawi Publishing Subscription Journals Hindawi Publishing Open Access CrossRef PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni Edition) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database (ProQuest) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest One Health & Nursing ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete ProQuest Health & Medical Research Collection Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central Korea ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database PubMed CrossRef |
| Database_xml | – sequence: 1 dbid: RHX name: Hindawi Publishing Open Access url: http://www.hindawi.com/journals/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: PIMPY name: ProQuest - Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 2090-0058 |
| Editor | Murata, Toshinori |
| Editor_xml | – sequence: 1 givenname: Toshinori surname: Murata fullname: Murata, Toshinori |
| EndPage | 7 |
| ExternalDocumentID | oai_doaj_org_article_7860637f82de45b9bcb7c9a6c640f008 PMC5932481 A590651028 29850205 10_1155_2018_4610129 1196593 |
| Genre | Journal Article |
| GeographicLocations | France Switzerland Germany |
| GeographicLocations_xml | – name: Switzerland – name: France – name: Germany |
| GrantInformation_xml | – fundername: AVOPH – fundername: CIL-ASSOC |
| GroupedDBID | 0R~ 188 24P 2UF 4.4 53G 5VS 7X7 8FI 8FJ AAFWJ AAMMB AAWTL ABDBF ABUWG ACCMX ACUHS ADBBV ADJCN ADRAZ AEFGJ AENEX AFKRA AFPKN AGXDD AHFXO AIDQK AIDYY ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV BENPR CCPQU DIK E3Z EBS EJD ESX F5P FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE IAO IEA IHR IHW IL9 ITC KQ8 M48 M~E O5R O5S OK1 PGMZT PHGZM PHGZT PIMPY PUEGO RHU RNS RPM TR2 TUS UKHRP UZ5 AAJEY AINHJ RHW RHX AAYXX AFFHD ALUQN CITATION ALIPV NPM 3V. 7XB 8FK AZQEC DWQXO K9. PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 7X8 5PM |
| ID | FETCH-LOGICAL-c635t-bd269b12c673be55d84f30e907a7c3d66968fad4df60fb4fe78e89943fd6c5983 |
| IEDL.DBID | RHX |
| ISICitedReferencesCount | 38 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000431198700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2090-004X |
| IngestDate | Fri Oct 03 12:51:24 EDT 2025 Tue Nov 04 01:55:32 EST 2025 Wed Oct 01 14:04:41 EDT 2025 Tue Oct 07 07:16:36 EDT 2025 Tue Nov 11 10:55:44 EST 2025 Tue Nov 04 18:19:24 EST 2025 Thu May 22 21:27:29 EDT 2025 Mon Jul 21 05:55:21 EDT 2025 Sat Nov 29 06:46:30 EST 2025 Tue Nov 18 20:58:05 EST 2025 Sun Jun 02 18:54:31 EDT 2024 Thu Sep 25 15:27:15 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2018 |
| Language | English |
| License | This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c635t-bd269b12c673be55d84f30e907a7c3d66968fad4df60fb4fe78e89943fd6c5983 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Academic Editor: Toshinori Murata |
| ORCID | 0000-0002-7918-7845 0000-0002-0391-2780 |
| OpenAccessLink | https://dx.doi.org/10.1155/2018/4610129 |
| PMID | 29850205 |
| PQID | 2407638476 |
| PQPubID | 4727242 |
| PageCount | 7 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_7860637f82de45b9bcb7c9a6c640f008 pubmedcentral_primary_oai_pubmedcentral_nih_gov_5932481 proquest_miscellaneous_2047919454 proquest_journals_2407638476 gale_infotracmisc_A590651028 gale_infotracacademiconefile_A590651028 gale_healthsolutions_A590651028 pubmed_primary_29850205 crossref_primary_10_1155_2018_4610129 crossref_citationtrail_10_1155_2018_4610129 hindawi_primary_10_1155_2018_4610129 emarefa_primary_1196593 |
| PublicationCentury | 2000 |
| PublicationDate | 2018-01-01 |
| PublicationDateYYYYMMDD | 2018-01-01 |
| PublicationDate_xml | – month: 01 year: 2018 text: 2018-01-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Cairo, Egypt |
| PublicationPlace_xml | – name: Cairo, Egypt – name: United States – name: New York |
| PublicationTitle | Journal of ophthalmology |
| PublicationTitleAlternate | J Ophthalmol |
| PublicationYear | 2018 |
| Publisher | Hindawi Publishing Corporation Hindawi John Wiley & Sons, Inc Wiley |
| Publisher_xml | – name: Hindawi Publishing Corporation – name: Hindawi – name: John Wiley & Sons, Inc – name: Wiley |
| References | 11 22 12 23 24 14 15 16 17 18 19 1 2 3 4 5 6 7 8 9 20 10 21 |
| References_xml | – ident: 16 doi: 10.2147/OPTH.S100764 – ident: 2 doi: 10.1001/archopht.1985.01050120030015 – ident: 11 doi: 10.1016/j.ophtha.2011.12.039 – ident: 12 doi: 10.1016/j.ophtha.2014.08.047 – ident: 23 doi: 10.1016/j.diabres.2016.09.015 – ident: 9 doi: 10.2337/dc10-0493 – ident: 20 doi: 10.1136/bjophthalmol-2013-303232 – ident: 22 doi: 10.1159/000453006 – ident: 1 doi: 10.1016/j.diabet.2009.06.002 – ident: 7 doi: 10.1016/j.ophtha.2009.04.049 – ident: 10 doi: 10.1185/03007995.2015.1081880 – ident: 6 doi: 10.1016/j.ophtha.2010.09.029 – ident: 14 doi: 10.1038/eye.2011.337 – ident: 17 doi: 10.1056/NEJMoa054481 – ident: 19 doi: 10.1016/j.ajo.2009.01.024 – ident: 15 doi: 10.1016/j.ophtha.2010.12.033 – ident: 8 doi: 10.1016/j.ophtha.2014.07.002 – ident: 24 doi: 10.1136/bjophthalmol-2015-307249 – ident: 3 doi: 10.1001/archophthalmol.2010.21 – ident: 4 doi: 10.1016/j.ophtha.2008.06.015 – ident: 18 doi: 10.1016/j.ophtha.2008.10.018 – ident: 21 doi: 10.1038/eye.2015.209 – ident: 5 doi: 10.1016/j.ophtha.2006.02.065 |
| SSID | ssj0000314550 |
| Score | 2.2710388 |
| Snippet | Purpose. To assess real-life efficacy of ranibizumab and treatment compliance of patients with vision loss secondary to diabetic macular edema (DME). Methods.... Purpose . To assess real-life efficacy of ranibizumab and treatment compliance of patients with vision loss secondary to diabetic macular edema (DME). Methods... To assess real-life efficacy of ranibizumab and treatment compliance of patients with vision loss secondary to diabetic macular edema (DME). A retrospective... To assess real-life efficacy of ranibizumab and treatment compliance of patients with vision loss secondary to diabetic macular edema (DME).PURPOSETo assess... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref hindawi emarefa |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1 |
| SubjectTerms | Blood pressure Care and treatment Diabetes Diabetic retinopathy Dropsy Edema Immunotherapy Ischemia Lasers Macular degeneration Medical research Medicine, Experimental Monoclonal antibodies Patient compliance Patients Pharmaceutical industry Sleep apnea Statistical analysis Type 2 diabetes |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQBRIXBOIVWMBIRRxQ1CS2Y_tYqq04QFWVIu0t8itqJEhRd7dV-fXM2Nl0g0C9cEw8ijOeyfibaPwNIbttzUIlTchVECznuuC5gl0qL2FzdYxxaUVqNiGPjtRioY-3Wn1hTViiB04LtycVQGwmW1X5wIXV1lnptKldzYt2OOYLqGcrmYoxmEUCbuwsV2g8Os0Xm6p3ISDhL9UeEo2XEVne7EeRtj-ezTVwbcYwfe8ME-Sr7m8w9M9qyq3t6fAheTDgSrqf9HlE7oT-Mbk-3ZSR0zlSRRh3TU3v6UGsI0d7066nx4ladUnxnyxNJTKdo19MLFGlcw_vSeOTgk8yJ6bvbPdr_cNYfIChJwA3889dG-jXEAupn5Bvh_PTg0_50GshdwA5Vrn1Va1tWblaMhuE8Iq3rAiQOhvpmK-RQ6c1nvu2LlrL2yBVgFSNs9bXTmjFnpKd_rwPzwnlzNTKOaUNgC3PLSQwCKy417Av6KrMyIfNijduICLHfhjfm5iQCNGgfZrBPhl5N0r_TAQc_5D7iMYbZZA2O94AZ2oGZ2puc6aMPBtMfzNXpFxkGXmDrtCk06ljWGj2hQYQhygtI--jBAYGUAdMms43wKIgxdZEcjaRhA_aTYZ3B3e7ReHZxhebIe4sG8zPIaJyWWfk7TiME2AtXR_O1yCDXQVKzQUHdZPrjhNVWglIIERG5MSpJ8s6Hem7s8hKDotUcVW--B92eEnuo6rpV9eM7Kwu1uEVuesuV93y4nX81H8DixVQXg priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lj9MwELagC9JeeIjHBgoYaREHFG0T24l9QrurrjhAVZVF6i1ybIeNBOnSB2j59cw4bkoQjwPH1KM44xmPZ6bjbwg5rDLm0ly7WDrBYq5GPJZwSsUJHK6GMZ6Xom02kU8mcj5X05BwW4Wyyq1N9IbaLgzmyI8w8gBd4Xn2-vJLjF2j8N_V0ELjOtlDpDI-IHsn48l01mVZEJxd-Dat6UjhFWo-31a_CwGBfyKPEHA88R7m7lzy8P3-jq6GZ92Z65sXGCh_q3_njv5aVfnTMXV2-38ZvENuBQeVHrcadZdcc809cnW-rUenY8Sc0OaK6sbSU1-QjopD64ZOW4zWFcXkLm1rbWpD32lf60rHFhil_k3OtjQz3dRl_X3zWZf4Ak1n4LfGb-vK0ffOV2TfJx_Oxuenb-LQtCE24Lus49KmmSqT1GQ5K50QVvKKjRzE4Do3zGYIxlNpy22VjaqSVy6XDmI-ziqbGaEke0AGzaJxB4RypjNpjFQavDbLS4iE0EPjVsEBo9IkIq-2IitMQDTHxhqfCh_ZCFGggIsg4Ii86KgvWySPP9CdoPQ7GsTf9j8slh-LsJ2LXELgx_JKptZxUarSlLlROjMZH1XgVkXkYdCd3Vweu5FF5BnqUtFec-3sS3EsFHiD6O5F5KWnQAsD7IBI24sSsCiI1dWjHPYowTKY3vBh0Nd_MDzcKmQRDNiq2GljRJ53wzgBFuU1brEBGmxPALtOcGC31f1uolRJAZGIiEje2xW9Ze2PNPWFhzeHRUq5TB79_bMek31kos2GDclgvdy4J-SG-bquV8unwQ78AFUaYAU priority: 102 providerName: ProQuest |
| Title | Treatment Efficacy and Compliance in Patients with Diabetic Macular Edema Treated with Ranibizumab in a Real-Life Setting |
| URI | https://search.emarefa.net/detail/BIM-1196593 https://dx.doi.org/10.1155/2018/4610129 https://www.ncbi.nlm.nih.gov/pubmed/29850205 https://www.proquest.com/docview/2407638476 https://www.proquest.com/docview/2047919454 https://pubmed.ncbi.nlm.nih.gov/PMC5932481 https://doaj.org/article/7860637f82de45b9bcb7c9a6c640f008 |
| Volume | 2018 |
| WOSCitedRecordID | wos000431198700001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: Directory of Open Access Journals customDbUrl: eissn: 2090-0058 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000314550 issn: 2090-004X databaseCode: DOA dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2090-0058 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000314550 issn: 2090-004X databaseCode: M~E dateStart: 20090101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2090-0058 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000314550 issn: 2090-004X databaseCode: 7X7 dateStart: 20130101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest - Publicly Available Content Database customDbUrl: eissn: 2090-0058 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000314550 issn: 2090-004X databaseCode: PIMPY dateStart: 20130101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2090-0058 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000314550 issn: 2090-004X databaseCode: BENPR dateStart: 20130101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVWIB databaseName: Wiley Online Library Open Access customDbUrl: eissn: 2090-0058 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000314550 issn: 2090-004X databaseCode: 24P dateStart: 20090101 isFulltext: true titleUrlDefault: https://authorservices.wiley.com/open-science/open-access/browse-journals.html providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELfYAIkXBOJjgVKMNMQDimhiO7Yft6nTkFhVlSGVp8hf0SJBhtYWNP567pw0kAGCl0qur3HsO9-He_4dIftVwUIuTUhVECzlesJTBVYqzcC4Osa4tKItNiFnM7Vc6nkHkrT6_S98sHYQnmfqDcKCg2naITtKoPAuTpb9UQoisItYizWfaLwnzZfbFPdrPx8Yn4jRHy_iGmibXiffPsdo-Fv9J5_zeurkL7bo-B652zmR9KDl-n1yIzQPyNXZNmecThEXwrgrahpPj2LSODKX1g2dtziqK4oHsLTNh6kdPTUxH5VOPbwnjU8KvqVZmKa29ffNZ2PxAYYuwLdM39VVoO9DzJp-SD4cT8-OTtKusELqwL9Yp9bnhbZZ7grJbBDCK16xSYA42UjHfIGAOZXx3FfFpLK8ClIFiMs4q3zhhFbsEdltLpqwRyhnplDOKW3As_LcQrSCXhT3GoyAzrOEvN6ueOk61HEsfvGpjNGHECXyp-z4k5CXPfWXFm3jL3SHyLyeBjGy4xcgN2W35UqpIDhjslK5D1xYbZ2VTpvCFXxSgeuTkMcd63-OFfEVWUKeoyiU7VXUXgeUB0KDx4YuWUJeRQrUAjAdYGl7mQEWBfG0BpSjASXsXjfo3u_E7R8THm1lseyUzKrEYBzUJ5dFQl703TgAJs414WIDNFhCINNccJhuK7r9QLlWAqIFkRA5EOrBsg57mvo8QpDDIuVcZU_-7-2fkjvYbE-uRmR3fbkJz8gt93Vdry7HZEcuZfxUY3LzcDqbL8bxaARa87en84_juN1_AGc9Q9w |
| linkProvider | Hindawi Publishing |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwELbKFgQXHuIVWKiRWnFAUTeJndgHhErZqqt2V6uySOUUHNuhkSBb9kFVfhS_kRnnURbxOPXAMeuRnXHm6R1_Q8hmHkc2TJT1heWRz2SP-QK8lB-Ac9VRxJKMV80mktFIHB_L8Rr53tyFwbLKxiY6Q22mGs_ItzHzAFlhSfzq9IuPXaPw39WmhUYlFgf2_AxStvnLwRv4vlthuNef7O77dVcBX4NzXfiZCWOZBaGOkyiznBvB8qhnIUlUiY5MjGgxuTLM5HEvz1huE2EhKWFRbmLNpYhg3itknYGwiw5ZHw-G4_ftqQ6CwXPXFjbsSbyyzY6banvOt8HZim0EOA9cRHvhB127AHcnWMGzat3DtRNMzM-K34W_v1Zx_uQW9279bxt6m9ysA3C6U2nMHbJmy7vkfNLU29M-YmoofU5VaeiuK7hHxaBFSccVBu2c4uE1rWqJCk2HytXy0r6BjaVuJmsqmiNVFlnxbflZZTiBokcQl_uHRW7pW-sqzu-Rd5fC7X3SKaelfUgoi1QstBZSQVRqWAaZHkagzEhwoDIMPPKiEZFU14jt2DjkU-oyN85TFKi0FiiPbLXUpxVSyR_oXqO0tTSIL-5-mM4-prW5ShMBiW2U5CI0lvFMZjpLtFSxjlkvh7DRIw9qWb1Yy2FTRh7ZQNlNq2u8rf1Md7iEaBfDWY88dxRoQYEd-KTVRRDYFMQiW6HsrlCC5dMrw5u1fvyD4W6jAGltoOfphfR75Fk7jAtg0WFpp0ugwfYLgWScAbuVrrULhVJwyLS4R5IVLVzZ1tWRsjhx8O2wSSETwaO_v9YGub4_GR6mh4PRwWNyAxmqTv66pLOYLe0TclV_XRTz2dPaBlHy4bK19Ad3x74A |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLbGBogXLuIWKMxIm3hAUdvETuwHhMbWimpbVY0hlafg2A6LBOnohan8NH4d5ziXUsTlaQ88pj6yc5xzdY-_Q8hOFoU2iJX1heWhz2SH-QK8lN8F56rDkMUpL5tNxMOhGI_laIN8r-_CYFllbROdoTYTjWfkbcw8QFZYHLWzqixidNB_df7Fxw5S-E9r3U6jFJFDu7yA9G32cnAA33o3CPq90_03ftVhwNfgaOd-aoJIpt1AR3GYWs6NYFnYsZAwqliHJkLkmEwZZrKok6Uss7GwkKCwMDOR5lKEMO8VsgUhOQMd2xoNjkfvmxMeBIbnrkVs0JF4fZuN68p7ztvgeEUbwc67Lrpd-UTXOsDdD1bwrBpXce0Mk_SL_Heh8K8VnT-5yP6t_3lzb5ObVWBO90pNukM2bHGXLE_rOnzaQ6wNpZdUFYbuu0J8VBiaF3RUYtPOKB5q07LGKNf0WLkaX9ozsMnUzWRNSXOiijzNvy0-qxQnUPQE4nX_KM8sfWtdJfo98u5SuL1PNotJYR8SykIVCa2FVBCtGpZCBoiRKTMSHKsMuh55UYtLoiskd2wo8ilxGR3nCQpXUgmXR3Yb6vMSweQPdK9R8hoaxB13P0ymH5PKjCWxgIQ3jDMRGMt4KlOdxlqqSEesk0E46ZEHldyu1nKYlaFHtlGOk_J6b2NXkz0uIQrGMNcjzx0FWlZgBz5peUEENgUxytYoW2uUYBH12vBOpSv_YLhVK0NSGe5ZstIEjzxrhnEBLEYs7GQBNNiWoSsZZ8BuqXfNQoEUHDIw7pF4TSPXtnV9pMjPHKw7bFLARPfR319rm1wH1UyOBsPDx-QG8lMeCLbI5ny6sE_IVf11ns-mTytzRMmHy1bSH9eKxsA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Treatment+Efficacy+and+Compliance+in+Patients+with+Diabetic+Macular+Edema+Treated+with+Ranibizumab+in+a+Real-Life+Setting&rft.jtitle=Journal+of+ophthalmology&rft.au=Best%2C+Anne-Laurence&rft.au=Fajnkuchen%2C+Franck&rft.au=Nghiem-Buffet%2C+Sylvia&rft.au=Grenet%2C+Typhaine&rft.date=2018-01-01&rft.pub=Hindawi&rft.issn=2090-004X&rft.eissn=2090-0058&rft.volume=2018&rft_id=info:doi/10.1155%2F2018%2F4610129&rft.externalDocID=10_1155_2018_4610129 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2090-004X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2090-004X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2090-004X&client=summon |